Elevated levels of plasma homocysteine are associated with both venous and arterial thrombosis. Homocysteine inhibits the function of thrombomodulin, an anticoagulant glycoprotein on the endothelial surface that serves as a cofactor for the activation of protein C by thrombin. The effects of homocysteine on thrombomodulin expression and protein C activation were investigated in cultured human umbilical vein endothelial cells and CV-1(18A) cells that express recombinant human thrombomodulin. Addition of5 mM homocysteine to endothelial cells produced slight increases in thrombomodulin mRNA and thrombomodulin synthesis without affecting cell viability. In both cell types, thrombomodulin synthesized in the presence of homocysteine remained sensitive to digestion with endoglycosidase H and failed to appear on the cell surface, suggesting impaired transit along the secretory pathway. In a cell-free protein C activation assay, homocysteine irreversibly inactivated both thrombomodulin and protein C in a process that required free thiol groups and was inhibited by the oxidizing agents diamide or N-ethylmaleimide. By inhibiting both thrombomodulin surface expression and protein C activation, homocysteine may contribute to the development of thrombosis in patients with cystathionine ft-synthase deficiency. (J. Clin. Invest.
Introduction
Thrombomodulin is an endothelial cell surface glycoprotein that promotes activation of the anticoagulant protein C and inhibits the procoagulant activities ofthrombin (1) (2) (3) . Negative regulation of thrombomodulin expression occurs when cultured endothelial cells are stimulated with endotoxin (4) or inflammatory cytokines such as interleukin-1 (5) and tumor necrosis factor-a (6) (7) (8) (9) (10) . The resulting decrease in protein C activation may contribute to the development of thrombosis and disseminated intravascular coagulation in patients with inflammatory disorders ( 1) .
Homocysteinemia caused by homozygous cystathionine ,3-synthase deficiency is associated with an increased incidence of vascular thrombosis (12) , and heterozygosity for this condi-tion has been reported to be an independent risk factor for premature arterial occlusive disease (13) (14) (15) (16) . The mechanisms by which elevated concentrations ofplasma homocysteine may lead to thrombosis or atherosclerosis are unknown. Homocysteine has been reported to produce endothelial cell injury when administered intravenously to baboons (17) , or when added directly to cultured endothelial cells (18, 19) . Enhanced Factor V activity was observed after incubation of human or bovine endothelial cells with homocysteine (20) . Recently, the binding of lipoprotein(a) to plasmin-modified fibrin was reported to be increased by homocysteine (21) . The effect ofhomocysteine on thrombomodulin activity was examined by Rodgers and Conn (22) , who observed reduced protein C activation after incubation of cultured endothelial cells with homocysteine, and suggested that homocysteine may compete with thrombin forbinding to thrombomodulin.
In this study, the mechanisms by which homocysteine decreases protein C activation were examined in human umbilical vein endothelial cells (HUVEC)1 and also in CV-1(18A) monkey kidney cells that express recombinant human thrombomodulin (23) . The results suggest that unlike tumor necrosis factor-a (7, 10) , homocysteine does not decrease thrombomodulin synthesis. Instead, homocysteine inhibits cell-surface thrombomodulin expression and irreversibly inactivates both thrombomodulin and protein C in a sulfhydryl-dependent process.
Methods
Materials. DME and fetal bovine serum (FBS) were from Gibco Laboratories (Grand Island, NY), and endothelial cell growth medium was from Clonetics Corp. (San Diego DL-homocysteine, DL-cysteine, DL-homocystine, DL-cystine, 2-mercaptoethanol, 1,10-phenanthroline, Nonidet P-40, L-1-p-tosylamino-2-phenylethyl chloromethylketone4TPCK-) treated trypsin, soybean trypsin inhibitor, chondroitin sulfate C, and Tris were from Sigma Chemical Co. (St. Louis, MO). Stock solutions of homocysteine, cysteine, 2-mercaptoethanol, NEM, and diamide were prepared immediately before use in 137 mM NaCl, 3 mM KC1, 15 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2 (PBS). Homocystine and cystine were dissolved in 0.1 N HCO before dilution in PBS and adjustment to pH 7.2 with 0.1 N NaOH.
Cell culture. HUVEC were purchased from Clonetics Corp. and cultured between passages 2 and 8 in endothelial cell growth medium (MCDB 131, 10 ng/ml epidermal growth factor, 0.4% bovine brain extract, 10 gg/ml heparin, 1 ug/ml hydrocortisone, 2% FBS, 50 ,g/ml gentamicin, and 0.5 Ag/ml amphotericin-B). CV-I(18A) monkey kidney cells expressing recombinant human thrombomodulin (23) were cultured in DME, 10% FBS, 100 U/ml penicillin, and 100 ,ug/ml streptomycin.
Nuclease SI protection analysis. HUVEC were incubated with 5 mM homocysteine for the indicated times, and total cellular RNA was isolated by the method of Chomczynski and Sacchi (24) . End-labeled probes specific for human thrombomodulin (from plasmid pUCI9TM12 [10] ) and human y actin (from plasmid pHFyA-1, provided by Dr. L. Kedes, University of Southern California, Pasadena [25] ) were prepared as described previously (10) , and hybridized overnight at 55°C with 20 or 5 jgofHUVEC RNA, respectively. Hybridization conditions, nuclease SI digestion, and analysis on denaturing PAGE were as described previously (10, 26) . Protected fragments of 243 and 325 nucleotides were detected for thrombomodulin and actin, respectively.
Metabolic labeling of cellular proteins. Confluent monolayers of HUVEC (-0.5 X 106 cells/well) were labeled in 1.0 ml cysteine-free or leucine-free medium containing dialyzed FBS. CV-1(18A) cells were labeled in cysteine-free medium without serum. For measurement of thrombomodulin synthesis, HUVEC were preincubated with 5 mM homocysteine for 0-22 h, washed three times with the appropriate labeling medium, and incubated for 2 h in 1.0 ml labeling medium contain- For determination of cell-surface thrombomodulin, labeled cells were washed with serum-free medium, and digested with 300 Ml of0.1 mg/ml TPCK-treated trypsin for 60 min at 23°C. Trypsin digestion was terminated by the addition of 150 Ml of 10 mg/ml soybean trypsin inhibitor. Control cells were treated with soybean trypsin inhibitor prior to addition of TPCK-treated trypsin.
Thrombomodulin immunoprecipitation and gel electrophoresis. After metabolic labeling, cells were washed with PBS, and cell lysates were prepared as described previously (23) . Thrombomodulin was immunoprecipitated with a rabbit polyclonal antiserum raised against a synthetic peptide corresponding to the carboxyl terminal sequence of human thrombomodulin (10) . Immunoprecipitated thrombomodulin was collected on protein A Sepharose as described previously (23) , and analyzed by SDS-PAGE under reducing conditions with 10% polyacryl- amide separating gels (27) , followed by autoradiography and fluorography (28 (29) .
Densitometry. Autoradiographic signals were quantitated with an UltraScan XL laser densitometer (Pharmacia LKB Biotechnology Inc., Piscataway, NJ).
Protein C activation. Human thrombin was prepared as described previously (23) . Protein C was purified from pooled human plasma by barium absorption and immunoaffinity chromatography with monoclonal antibody hC-2 (provided by Dr. J. Miletich, Washington University, St. Louis, MO) as described previously (30). Human antithrombin III was provided by Dr. Douglas Tollefsen (Washington University, St. Louis, MO). CV-l(18A) cell lysate was used as the source ofthrombomodulin in cell-free protein C activation assays. These cells, which express 220,000 molecules of thrombomodulin per cell (23) , were lysed in assay buffer (50 mM Tris-chloride, pH 8.0, 2 mM CaCl2, 100 mM NaCl, 0.1% bovine albumin, 0.6% (vol/vol) Triton X-100), and nuclei were removed by centrifugation. Thrombomodulin-dependent protein C activation was measured in assay buffer containing 13 nM thrombin, 0.8 uM protein C, 0.16 nM thrombomodulin, and various concentrations of homocysteine. Thrombomodulin-independent protein C activation was measured either in assay buffer or calcium-free assay buffer containing 5 mM EDTA. Reactions were incubated for 30 min at 37°C, antithrombin III and heparin were added to inhibit residual thrombin activity, and activated protein C was determined by hydrolysis of the chromogenic substrate S-2366 as described previously (10) . For concentration curves, an exponential decay function (y = AeBx) was fitted to the data using the RS/I system (BBN Software Products Corp., Cambridge, MA), and IC,0 was defined as the concentration of homocysteine that resulted in 50% inhibition of protein C activation.
For preincubation experiments, thrombin, CV-I (1 8A) thrombomodulin, or protein C were incubated in assay buffer for 60 min at 370C with the indicated concentrations ofsulfhydryl agents. Following preincubation, samples were diluted 25-fold with assay buffer, and protein C activation was performed for 30 min at 370C. In control experiments without preincubation, protein C activation was unaffected by direct addition of diluted sulfhydryl agents.
Results
In previous studies, endothelial cell cytotoxicity has been reported to occur in proportion to the concentrations of both homocysteine and serum in the culture medium (18, 19). The medium used in the present study contained 2% fetal bovine serum, and concentrations of homocysteine from 0.01 to 5 mM did not produce cell detachment or significant loss of HUVEC viability (< 10% trypan blue positivity). Increased cell lysis (-40%) was observed after incubation with 10 mM homocysteine for 24 h. In the presence of 1-5 mM homocysteine, the cells adopted an elongated shape similar to that seen after stimulation with tumor necrosis factor (31).
Effect of homocysteine on thrombomodulin synthesis. To determine whether homocysteine affected thrombomodulin mRNA expression, total cellular RNA was isolated from HUVEC at various times after addition of 5 mM homocysteine, and thrombomodulin or actin mRNAs were assayed by nuclease S1 protection ( Fig. 1 A) . Quantitative densitometry showed that thrombomodulin mRNA, normalized to actin mRNA, increased by two-to fourfold after 24 h of incubation with homocysteine ( Fig. 1 A, lane 6) . The slight decrease in thrombomodulin mRNA observed 2-4 h after addition of homocysteine in Fig. 1 A (lanes 2 and 3) was not reproducibly observed in other experiments.
Similar results were obtained when thrombomodulin synthesis was examined by pulse labeling HUVEC for 2 h with [35S]cysteine (Fig. 1 B) (Fig. 2 A, lanes 5  and 6) . In the presence of 5 mM homocysteine however, the 80,000-D band remained the major product after 8 h (Fig. 2 A,  lanes 9-11) . In separate experiments with homocysteine, no mature 95,000-D thrombomodulin was observed after labeling for up to 24 h, and no immunoprecipitable thrombomodulin was detectable in the culture medium. Thrombomodulin glycosylation was examined further in CV-l(1 8A) cells that express recombinant human thrombomodulin (23) . The effect ofhomocysteine on the time course of thrombomodulin labeling in these cells was similar to that in HUVEC (Fig. 2 B) . As previously observed (23), the apparent molecular weight on SDS-PAGE of CV-1(1 8A) thrombomodulin was 5,000 D larger than HUVEC thrombomodulin. A nonspecific band migrating near the top ofthe gel was variably observed after long labeling times with both immune and nonimmune serum. The asparagine-linked oligosaccharide struc- 
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tures of recombinant thrombomodulin were evaluated by digestion with N-glycanase or endoglycosidase H. The mobility of radiolabeled thrombomodulin synthesized in the absence of homocysteine increased after digestion with N-glycanase ( Fig.  3 A, lane 3) , but was unaffected by digestion with endoglycosidase H (Fig. 3 A, lane 5) , demonstrating that complex-type asparagine-linked oligosaccharides were present. In contrast, thrombomodulin synthesized in the presence of homocysteine migrated with increased electrophoretic mobility after digestion with either N-glycanase or endoglycosidase H (Fig. 3 A,  lanes 7 and 9) , consistent with the presence of high-mannose oligosaccharide chains (36) . These findings suggest that the increased electrophoretic mobility of thrombomodulin synthesized in the presence of homocysteine resulted from impaired processing of asparagine-linked oligosaccharides. Attachment of a chondroitin sulfate glycosaminoglycan to recombinant soluble human thrombomodulin has been shown to increase the catalytic efficiency of protein C activation (34 (Fig. 3 B, lane 6 ). This 160,000-D band was not immunoprecipitated by nonimmune serum (Fig. 3 B , lane 10). After chondroitinase digestion, the 160,000-D band was no longer observed, but the 100,000-D band was unchanged in mobility and intensity (Fig. 3 B, lane 7) . When cells were labeled with [35S]cysteine, the 160,000-D band accounted for < 10% of immunoprecipitated thrombomodulin (Fig. 3 B,  lane 2) , suggesting that only a small fraction of CV-1(1 8A) thrombomodulin is associated with chondroitin sulfate. When cells were incubated with [35S]sulfate in the presence of homocysteine, decreased labeling of both the 160,000-and 100,000-D bands occurred (Fig. 3 B, lanes 8 and 9) , suggesting that homocysteine inhibits the incorporation of sulfate into both chondroitinase-sensitive and chondroitinase-resistant structures.
Thrombomodulin oligosaccharide processing was examined further as a function of homocysteine concentration. With homocysteine concentrations < 1.0 mM, mature thrombomodulin was the major product immunoprecipitated from [35S]cysteine-labeled cells (Fig. 4 A, lanes I and 2) . When the homocysteine concentration was increased, a progressive decrease in mature thrombomodulin and increase in incompletely glycosylated thrombomodulin occurred (Fig. 4 A, lanes  3-6) . Complete inhibition of complex-type asparagine-linked glycosylation was observed with homocysteine concentrations 2 5 mM. Increased mobility ofthrombomodulin also occurred when CV-l( 1 8A) cells were incubated with millimolar concentrations of the sulfhydryl agent 2-mercaptoethanol (Fig. 4 B) , suggesting that oligosaccharide processing may be sensitive generally to thiol reducing agents.
Effect ofhomocysteine on thrombomodulin surface expression. The effect of homocysteine on cell-surface thrombomodulin expression was evaluated by digesting intact CV-(1( 8A) cells with trypsin. As demonstrated by resistance to exogenous trypsin, thrombomodulin remained intracellular after labeling for 1 h either with or without 5 mM homocysteine (Fig. 5 A,  lanes 3 and 7) . After labeling for 8 h in the absence ofhomocys- tion of protein C by thrombin was accelerated -20-fold by 0.16 nM thrombomodulin (Fig. 6 A) . Addition of homocysteine inhibited thrombomodulin-dependent protein C activation in a concentration-dependent manner, with ICW = 2.2±0.3 mM (SD). High concentrations of homocysteine also appeared to inhibit thrombomodulin-independent protein C activation (Fig. 6 A) . This effect was confirmed when protein C activation was measured in the absence of calcium ions, a condition that enhances thrombomodulin-independent activity (1); in this case homocysteine inhibited with IC50 -= 1.3±0.4 mM (SD) (Fig. 6 B) . The similarity of this concentration dependence to that reported after preincubation of endothelial cells with homocysteine (22) suggested that homocysteine may directly inactivate one or more components of the reaction.
To determine which components of the reaction were sensitive to homocysteine, thrombin, protein C, and thrombomodulin were individually preincubated with 5 mM homocysteine for 60 min at 37°C. After preincubation, the samples were diluted to a final homocysteine concentration of 0.2 mM to prevent further inhibition by homocysteine during the subsequent protein C activation assay. As shown in Fig. 7 , preincubation of protein C or thrombomodulin with homocysteine decreased protein C activation by > 80%, but preincubation with thrombin had little effect. These results suggest that inactivation of both thrombomodulin and protein C contribute to the decreased protein C activation observed in the presence of homocysteine. The specificity of inactivation was examined using additional sulfhydryl agents. Protein C activation decreased following preincubation of thrombomodulin with 5 mM homocys- Buffer Homo Cysteine 2-ME Homo Cystine with 5 mM concentracysteine cystine tions ofthe indicated sulfhydryl agents. Assay conditions were identical to those in Fig. 7 , and thrombomodulin-independent activity was 10.4±0.2 pmol/h per ml. teine, cysteine, or 2-mercaptoethanol, all ofwhich contain free thiol groups (Fig. 8) . No inhibition was observed following preincubation with the same concentration of the disulfides homocystine or cystine. Similar results were obtained after preincubation of protein C (data not shown). Further evidence for thiol-dependent inactivation was provided by the addition of the oxidizing agents N-ethylmaleimide (NEM) or diamide. Preincubation of thrombomodulin or protein C with 10 mM NEM or diamide completely prevented inactivation by 5 mM homocysteine (Table I) . When thrombomodulin or protein C was first inactivated with 5 mM homocysteine no recovery of cofactor activity occurred during a subsequent 60 min incubation with 10 mM NEM or diamide (data not shown). Therefore, homocysteine inactivates both thrombomodulin and protein C by an irreversible, sulfhydryl-dependent mechanism.
Discussion
Although cystathionine (.-synthase deficiency has been implicated as an independent risk factor for premature vascular dis- ease (13) (14) (15) (16) , the mechanisms by which homocysteinemia may predispose to thrombosis or atherosclerosis remain largely unknown. This study suggests that homocysteine may compromise the anticoagulant potential of vascular endothelial cells indirectly by decreasing cell-surface thrombomodulin expression, and directly by inhibiting protein C activation. Unlike tumor necrosis factor-a, which inhibits protein C activation primarily by decreasing thrombomodulin gene transcription (7, 10) , incubation of HUVEC with homocysteine produced slight (two-to fourfold) increases in thrombomodulin synthesis and mRNA level. Thrombomodulin synthesized by homocysteine-treated cells was not expressed on the cell surface, however, and contained incompletely processed asparagine-linked oligosaccharide chains. In addition, direct inactivation of thrombomodulin and protein C occurred after preincubation with homocysteine. Inhibition of both thrombomodulin surface expression and protein C activation occurred at homocysteine concentrations that did not produce changes in total cellular mRNA or cell viability.
Patients with cystathionine f3-synthase deficiency may have plasma concentrations offree homocysteine up to 0.2 mM during fasting, and higher concentrations after methionine loading Inhibition of thrombomodulin glycosylation by homocysteine may contribute to decreased protein C activation. Although asparagine-linked oligosaccharides do not appear to be necessary for thrombin binding (39) , glycosaminoglycan attachment has been shown to affect both protein C activation (34) and the direct anticoagulant activities ofthrombomodulin (33) (34) (35) . Glycosaminoglycan association with CV-1(18A) thrombomodulin appears to be inefficient, because the chondroitinase-sensitive 160,000-D band represented < 10% of total [35S]cysteine-labeled thrombomodulin (Fig. 3 B) (41) . Oxidation-reduction mechanisms have been shown to be important in cytoplasmic processes, including regulation of ferritin translation (42) ,fos-jun DNA binding (43) , and NF-KB activation (43) . The results presented here suggest that cell-surface thrombomodulin expression is inhibited by alteration of the extracellular redox potential. Both decreased thrombomodulin cell-surface expression and direct inhibition of protein C activation may contribute to the increased risk of vascular disease in patients with homocysteinemia.
